EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
复制标题
DOI：
10.1016/j.jhep.2021.01.032
复制
发表时间：
2021-04
影响因子：
25.7
通讯作者：
Shouval D
中科院分区：
文献类型：
--
作者：
Cornberg M;Buti M;Eberhardt CS;Grossi PA;Shouval D
根据世界卫生组织最近的一项估计，2019年起源于中国的严重急性呼吸综合征冠状病毒2型大流行已在全球蔓延，截至2021年1月，全球感染人数近1亿。慢性肝病(CLD)患者，特别是肝硬变、肝胆恶性肿瘤、肝移植的候选者和肝移植后免疫抑制的个体，总体上似乎面临更高的感染风险，这反过来又会导致死亡率的增加。SARS-CoV-2感染也是如此，尤其是肝硬变患者，出现严重的新冠肺炎病程的风险很高。因此，对慢性阻塞性肺疾病患者尽早接种包括SARS-CoV-2在内的各种病原体疫苗是一项重要的保护措施。然而，由于这些患者的免疫反应受损，通过免疫接种的即时和长期保护性反应可能是不完整的。目前的SARS-CoV-2大流行导致了几种候选疫苗的异常快速的发展。这些SARS-CoV-2候选疫苗中的一小部分已经在健康个体中进行了第三阶段的安慰剂对照临床试验，证明了短期安全性、免疫原性和有效性。然而，尽管美国和欧洲的监管机构已经批准了其中一些疫苗用于临床，但关于慢性阻塞性肺疾病、肝硬变、肝胆癌和肝移植接受者的免疫原性、保护期和长期安全性的信息尚未产生。这篇综述总结了疫苗安全性、免疫原性和在一般患者群体中的有效性的数据，并讨论了这一知识对引入新的SARS-CoV-2疫苗的意义。
According to a recent World Health Organization estimate, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, which originated in China in 2019, has spread globally, infecting nearly 100 million people worldwide by January 2021. Patients with chronic liver diseases (CLD), particularly cirrhosis, hepatobiliary malignancies, candidates for liver transplantation, and immunosuppressed individuals after liver transplantation appear to be at increased risk of infections in general, which in turn translates into increased mortality. This is also the case for SARS-CoV-2 infection, where patients with cirrhosis, in particular, are at high risk of a severe COVID-19 course. Therefore, vaccination against various pathogens including SARS-CoV-2, administered as early as possible in patients with CLD, is an important protective measure. However, due to impaired immune responses in these patients, the immediate and long-term protective response through immunisation may be incomplete. The current SARS-CoV-2 pandemic has led to the exceptionally fast development of several vaccine candidates. A small number of these SARS-CoV-2 vaccine candidates have already undergone phase III, placebo-controlled, clinical trials in healthy individuals with proof of short-term safety, immunogenicity and efficacy. However, although regulatory agencies in the US and Europe have already approved some of these vaccines for clinical use, information on immunogenicity, duration of protection and long-term safety in patients with CLD, cirrhosis, hepatobiliary cancer and liver transplant recipients has yet to be generated. This review summarises the data on vaccine safety, immunogenicity, and efficacy in this patient population in general and discusses the implications of this knowledge on the introduction of the new SARS-CoV-2 vaccines.
登录
查看更多内容
DOI：
10.1016/j.cmi.2021.01.005
发表时间：
2021-01-20
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
L'Huillier AG;Meyer B;Andrey DO;Arm-Vernez I;Baggio S;Didierlaurent A;Eberhardt CS;Eckerle I;Grasset-Salomon C;Huttner A;Posfay-Barbe KM;Royo IS;Pralong JA;Vuilleumier N;Yerly S;Siegrist CA;Kaiser L;Geneva Centre for Emerging Viral Diseases
通讯作者：
Geneva Centre for Emerging Viral Diseases
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
158.5
作者：
Confavreux, C;Suissa, S;Vukusic, S
通讯作者：
Vukusic, S
DOI：
10.1016/j.cvsm.2017.10.005
发表时间：
2018-03-01
影响因子：
1.9
作者：
Gershwin, Laurel J.
通讯作者：
Gershwin, Laurel J.
影响因子：
2.1
作者：
Danziger-Isakov, Lara;Kumar, Deepali
通讯作者：
Kumar, Deepali